# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Leerink Partners analyst Michael Cherny downgrades CVS Health (NYSE:CVS) from Outperform to Market Perform and announces $60...
Cantor Fitzgerald analyst Sarah James downgrades CVS Health (NYSE:CVS) from Overweight to Neutral and lowers the price targe...
CVS Health Q1 sales of $88.4 billion, up 3.7% Y/Y. Adjusted EPS at $1.31, down from $2.20. Health Care Benefits segment sees st...
A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc...